Torrent Pharmaceuticals reported a 30% increase in net profit, reaching ₹591 crore for Q2 FY26. Revenue increased by 14% year-over-year to ₹3,302 crores. The company’s operating EBITDA stood at ₹1,083 crores with a margin of 32.8%. Strong performance in key markets like India and the US drove the results. A recent acquisition is expected to further boost growth.
Strong Q2 FY26 Performance
Torrent Pharmaceuticals announced a strong financial performance for Q2 FY26, with net profit increasing by 30% to ₹591 crore. Revenue for the quarter reached ₹3,302 crores, a 14% increase compared to the same period last year. Operating EBITDA stood at ₹1,083 crores, representing a margin of 32.8%.
Key Financial Highlights
- Revenue: ₹3,302 crores (up 14% YoY)
- Operating EBITDA: ₹1,083 crores (up 15% YoY)
- Operating EBITDA Margin: 32.8%
- Net Profit: ₹591 crores (up 30% YoY)
Segmental Performance
The company experienced growth in key markets:
- India: Revenues increased by 12% to ₹1,820 crores, driven by strong performance in focus therapies.
- Brazil: Revenues increased by 21% to ₹318 crores (13% in constant currency).
- United States: Revenues increased by 26% to ₹337 crores (21% in constant currency).
- Germany: Revenues increased by 5% to ₹303 crores (-5% in constant currency due to supply chain issues).
Recent Developments
Torrent Pharma received approvals from the Competition Commission of South Africa and the Competition Commission of India for its acquisition of a controlling stake in J.B. Chemicals & Pharmaceuticals Limited. This acquisition is anticipated to contribute significantly to future growth. The transaction involves acquiring 46.39% equity stake and merging JB Pharma with Torrent. Exceptional items for the quarter pertain to regulatory and statutory filing fees related to this transaction.
Full Year Outlook
The company is expected to continue its growth trajectory, driven by strong performance in key markets, new product launches, and the integration of JB Pharma. R&D expenditure for the quarter was ₹156 crores, representing 5% of revenue. The company remains focused on investing in R&D to drive future growth.
Source: BSE
